Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
31 results about "Cytochrome P450 Inhibitors" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Methods for Treating HCV
ActiveUS20130102526A1Improve pharmacokineticsImprove bioavailabilityBiocideDipeptide ingredientsCytochrome P450 InhibitorsShort duration
The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
Owner:ABBVIE INC
Methods for Treating HCV
ActiveUS20130102525A1Avoid side effectsImprove pharmacokineticsBiocideDipeptide ingredientsCytochrome P450 InhibitorsShort duration
The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
Owner:ABBVIE INC
Methods for treating HCV
ActiveUS8466159B2Improve pharmacokineticsImprove bioavailabilityBiocideDipeptide ingredientsCytochrome P450 InhibitorsShort duration
The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
Owner:ABBVIE INC
Methods for treating HCV
ActiveUS8492386B2Improve pharmacokineticsImprove bioavailabilityBiocideDipeptide ingredientsCytochrome P450 InhibitorsShort duration
The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
Owner:ABBVIE INC
Naphthylene derivatives as cytochrome P450 inhibitors
Compounds of the formula and pharmaceutically acceptable salts thereof, wherein n1, n2, n3, n4, G1, Q1, Z, R1, R2, R3, R4a, R4b, R5a, and R5b are defined herein, inhibit the cytochrome P450RAI enzyme and are useful for the treatment and / or prevention of various diseases and conditions which respond to treatment by retinoids and by naturally occurring retinoic acid.
Owner:OSI PHARMA INC
Method for improving pharmacokinetics
InactiveUS20100272682A1Improve bioavailabilityIncreased blood levelsBiocidePeptide/protein ingredientsBlood levelCo administration
The object of the present invention is to elevate the blood levels of a compound of formula I by co-administration with a cytochrome P450 inhibitor.
Owner:TRAN JONATHAN Q
Methods for treating HCV
ActiveUS8853176B2Improve pharmacokineticsImprove bioavailabilityBiocideDipeptide ingredientsCytochrome P450 InhibitorsShort duration
The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
Owner:ABBVIE INC
Methods for Treating HCV
ActiveUS20130102558A1Avoid side effectsImprove pharmacokineticsBiocideDipeptide ingredientsCytochrome P450 InhibitorsShort duration
The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
Owner:ABBVIE INC
Naphthylene derivatives as cytochrome P450 inhibitors
The present invention discloses compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein n1, n2, n3, n4, G1, Q1, Z, R1, R2, R3, R4a, R4b, R5a, and R5b are as described herein , which inhibits the cytochrome P450 RAI enzyme and is useful for the treatment and / or prevention of a variety of diseases and conditions that respond to treatment with retinoids and naturally occurring retinoic acid.
Owner:OSI PHARMA INC
Naphthylene derivatives as cytochrome P450 inhibitors
Compounds of the formulaand pharmaceutically acceptable salts thereof, wherein n1, n2, n3, n4, G1, Q1, Z, R1, R2, R3, R4a, R4b, R5a, and R5b are defined herein, inhibit the cytochrome P450RAI enzyme and are useful for the treatment and / or prevention of various diseases and conditions which respond to treatment by retinoids and by naturally occurring retinoic acid.
Owner:OSI PHARMA INC
Cytochrome p450 inhibitors and uses thereof
ActiveUS20140018401A1Improve responseOrganic active ingredientsBiocideDiseaseCytochrome P450 Inhibitors
Owner:ANGION BIOMEDICA CORP
Combinations of opioid receptor ligands and cytochrome p450 inhibitors
InactiveCN108601775AImprove bioavailabilityOrganic active ingredientsNervous disorderMedicineCytochrome P450 Inhibitors
This application described compounds that can act as opioid receptor ligands, and compositions comprising the compounds and cytochrome P450 inhibitors, which can be used in the treatment of, for example, pain and pain related disorders.
Owner:TREVENA INC
Cytochrome P450 inhibitors and uses thereof
The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.
Owner:ANGION BIOMEDICA CORP
Method for predicting inhibition concentration of cytochrome P450 enzyme CYP1A2 inhibitor by utilizing simplified partial least squares
ActiveCN104866710AReduce development riskImprove forecast qualitySpecial data processing applicationsCytochrome P450 InhibitorsCYP1A2
The invention discloses a method for predicting inhibition concentration of a cytochrome P450 enzyme CYP1A2 inhibitor by utilizing simplified partial least squares. The method comprises the steps of: 1) collecting, processing and optimizing sample sets; 2) constructing molecular descriptors of the inhibitor; 3) preliminarily screening molecular descriptors of the inhibitor; 4) scaling data sets of molecular descriptors of the inhibitor again; 5), dividing data sets of molecular descriptors of the inhibitor; 6), setting up a QSAR model; and 7) predicting inhibition concentration of the cytochrome P450 enzyme CYP1A2 inhibitor.The method utilizes the method of partial least squares (PLS) to further estimate and simplify constituents of partial least squares (PLS) in the presence of serious multiple correlations of independent variables on the basis of regression modeling and uses the simplified method of partial least squares (SIMPLS) to precisely predict inhibition concentration of the cytochrome P450 inhibitor.
Owner:居李生物科技(北京)有限公司
Methods for Treating HCV
InactiveUS20150024999A1Improve pharmacokineticsImprove bioavailabilityOrganic active ingredientsBiocideCytochrome P450 InhibitorsShort duration
The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
Owner:ABBVIE INC
Cytochrome P450 inhibitors and uses thereof
The present invention provides compounds having the general structural formula (I) (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.
Owner:ANGION BIOMEDICA CORP
Cytochrome p450 inhibitors and uses thereof
ActiveUS20170247363A1Conveniently preparedOrganic active ingredientsOrganic chemistryMedicineCytochrome P450 Inhibitors
The present invention provides compounds having the general structural formula (I) (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.
Owner:ANGION BIOMEDICA CORP
Cytochrome p450 inhibitors and uses thereof
ActiveUS20180148438A1Prevention lesseningReduce severityOrganic chemistryDiseaseCytochrome P450 Inhibitors
The present invention provides compounds having the general structural formula (I)and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.
Owner:ANGION BIOMEDICA CORP
Cytochrome p450 inhibitors and uses thereof
ActiveUS20130102643A1Prevention lesseningReduce severityBiocideOrganic active ingredientsCytochrome P450 InhibitorsAnti fibrotic
The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.
Owner:ANGION BIOMEDICA CORP
Cytochrome P450 inhibitors and uses thereof
Owner:ANGION BIOMEDICA CORP
Methods for treating hcv
InactiveUS20160228496A1Improve pharmacokineticsImprove bioavailabilityOrganic active ingredientsDipeptide ingredientsMedicineCytochrome P450 Inhibitors
The present invention features therapies for the treatment of HCV comprising direct-acting antiviral agents. Preferably, the treatment is administered to an HCV-infected patient who has been tested to determine methylation status of a CpG island within a promoter region of the IL28B gene. In one aspect, the therapies comprise administering one or more direct acting antiviral agents and, optionally ribavirin, to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2, therapeutic agent 3, an inhibitor of cytochrome P450 (e.g., ritonavir), and / or ribavirin.
Owner:ABBVIE INC
Methods for treating hcv
InactiveUS20160237491A1Improve pharmacokineticsImprove bioavailabilityOrganic active ingredientsDipeptide ingredientsInfected patientMedicine
The present invention features therapies for the treatment of HCV comprising direct-acting antiviral agents. Preferably, the treatment is administered to an HCV-infected patient who has been tested to determine methylation status of a CpG island within a promoter region of the IL28B gene. In one aspect, the therapies comprise administering one or more direct acting antiviral agents and, optionally ribavirin, to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2, therapeutic agent 3, an inhibitor of cytochrome P450 (e.g., ritonavir), and / or ribavirin.
Owner:ABBVIE INC
Pyrazole derivatives as cytochrome P450 inhibitors
InactiveCN101511812AOrganic active ingredientsOrganic chemistryCytochrome P450 InhibitorsPharmaceutical formulation
Owner:PFIZER PRODS ETAT DE CONNECTICUT
Naphthylene derivatives as cytochrome P450 inhibitors
Compounds of the formula (I); and pharmaceutically acceptable salts thereof, wherein n1, n2, n3, n4, G <1>,Q<1>, Z, R<1>, R<2>, R<3>, R<4a>, R<4b>, R<5a>, and R<5b> are defined herein, inhibit the cytochrome P450RAI enzyme and are useful for the treatment and / or prevention of various diseases and conditions which respond to treatment by retinoids and by naturally occurring retinoic acid.
Owner:OSI PHARMA INC
Potent and selective inhibitors of cytochrome p450
Inhibitors of the enzyme cytochrome P450 (CYP), including 1B1 (CYP1B1), 1A1 (CYP1A1) and 19A1 (CYP19A1) are provided, and are useful in medical applications. Disclosed are highly potent and selective compounds that can be used in chemoprevention to ameliorate malignant changes induced by CYP, or to aid in treatment, including restoration of chemotherapeutic efficacy.
Owner:UNIV OF KENTUCKY RES FOUND
Method for improving pharmacokinetics
InactiveUS20170119739A1Improve bioavailabilityImprove the level ofSulfur/selenium/tellurium active ingredientsAntiviralsCo administrationCytochrome P450 Inhibitors
The object of the present invention is to inhibit oxidative metabolism of a compound of formula I by co-administration with ritonavir, a cytochrome P450 inhibitor.
Owner:ROCHE PALO ALTO LLC
Tetrazole derivatives as cytochrome p450 inhibitors
According to the invention there is provided a compound of formula I, wherein R1 and R2 have meanings given in the description, which compounds are useful in the treatment of skin disorders and other diseases.
Owner:C26 BIOSCI AB
Methods and uses of cytochrome p450 inhibitors
Methods are provided for treating or preventing chronic obstructive pulmonary diseases such as emphysema, and fibrotic diseases including heart, liver, kidney and vascular diseases, by administering to a subject a pharmaceutical composition comprising a compound that inhibits cytochrome P450RA or CYP26.
Owner:ANGION BIOMEDICA CORP
Tetrazole derivatives as cytochrome P450 inhibitors
According to the invention there is provided a compound of formula I, wherein R1 and R2 have meanings given in the description, which compounds are useful in the treatment of skin disorders and other diseases.
Owner:C26 BIOSCI AB
Method for Predicting Inhibitory Concentration of Cytochrome p450 1A2 Inhibitors
ActiveCN104866710BReduce development riskImprove forecast qualitySpecial data processing applicationsData setCytochrome P450 Inhibitors
The invention discloses a method for predicting inhibition concentration of a cytochrome P450 enzyme CYP1A2 inhibitor by utilizing simplified partial least squares. The method comprises the steps of: 1) collecting, processing and optimizing sample sets; 2) constructing molecular descriptors of the inhibitor; 3) preliminarily screening molecular descriptors of the inhibitor; 4) scaling data sets of molecular descriptors of the inhibitor again; 5), dividing data sets of molecular descriptors of the inhibitor; 6), setting up a QSAR model; and 7) predicting inhibition concentration of the cytochrome P450 enzyme CYP1A2 inhibitor.The method utilizes the method of partial least squares (PLS) to further estimate and simplify constituents of partial least squares (PLS) in the presence of serious multiple correlations of independent variables on the basis of regression modeling and uses the simplified method of partial least squares (SIMPLS) to precisely predict inhibition concentration of the cytochrome P450 inhibitor.
Owner:居李生物科技(北京)有限公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com